Clinical Trial Update: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating IBI343 monotherapy versus investigator's choice in previously treated CLDN18.2-positive, HER2-negative gastric or gastroeso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• IBI343

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING